Direct Oral Anticoagulants in Patients on Chronic Dialysis and Concomitant Atrial Fibrillation: A Common Clinical Impasse
Key result
DOACs lack large randomized trials for AF in chronic hemodialysis despite apixaban and warfarin approvals.
Why the study?
Data from major trials cannot be extended to chronic dialysis patients with AF due to a lack of large randomized studies.
Are direct oral anticoagulants safe and effective compared to warfarin in patients on chronic hemodialysis with concomitant atrial fibrillation?
Structured PICO
Are direct oral anticoagulants safe and effective compared to warfarin in patients on chronic hemodialysis with concomitant atrial fibrillation?
P
Population
Patients on chronic hemodialysis with concomitant atrial fibrillation
I
Intervention
Direct oral anticoagulants (DOACs)
C
Comparator
Warfarin
This review highlights the scarcity of robust data for DOAC use in dialysis patients with AF and provides guidance on therapy selection based on current evidence.
Limitations
- Lack of large randomized studies
- Scarcity of data
Authors
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
Scant randomized data limits confident DOAC selection in hemodialysis AF; leaves open the need for dedicated RCTs.
Cite This Study
Ktenopoulos et al. (2022) conducted a review in Atrial fibrillation and chronic dialysis. Direct Oral Anticoagulants (DOACs) vs. Warfarin was evaluated. Direct oral anticoagulants lack large randomized trial data in patients on chronic hemodialysis with atrial fibrillation, though apixaban and warfarin are currently FDA-approved for this population.